---
layout: post
title: "Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:57:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-23677
original_published: 2023-10-26 00:00:00 +0000
significance: 8.00
---

# Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** October 26, 2023 00:00 UTC
**Document Number:** 2023-23677

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities." FDA is issuing this draft guidance to describe how we request and conduct voluntary remote interactive evaluations at facilities where drugs are manufactured, processed, packed, compounded, or held, and at facilities covered under FDA's bioresearch monitoring program. FDA may consider the use of a remote interactive evaluation for any of the inspection program areas described in the guidance. FDA is also announcing the withdrawal of the guidance entitled "Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency."

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/10/26/2023-23677/remote-interactive-evaluations-of-drug-manufacturing-and-bioresearch-monitoring-facilities-draft)
- API: https://www.federalregister.gov/api/v1/documents/2023-23677

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
